About Iovance Biotherapeutics
Iovance Biotherapeutics is a company based in San Carlos (United States) founded in 2007 by Robert T Brooke. It operates as a HealthTech. The company has 838 employees as of December 31, 2024. Iovance Biotherapeutics has completed 1 acquisition, including Proleukin. Iovance Biotherapeutics offers products and services including Amtagvi and Proleukin. Iovance Biotherapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
- Headquarter San Carlos, United States
- Employees 838 as on 31 Dec, 2024
- Founders Robert T Brooke
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Iovance Biotherapeutics, Inc.
-
Annual Revenue
$164.07 M13698.99as on Dec 31, 2024
-
Net Profit
$-372.18 M16.18as on Dec 31, 2024
-
EBITDA
$-351.67 M17.72as on Dec 31, 2024
-
Latest Funding Round
$100 M (USD), Post-IPO
Jun 15, 2016
-
Investors
Orbimed
& 2 more
-
Employee Count
838
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Iovance Biotherapeutics
Iovance Biotherapeutics is a publicly listed company on the NASDAQ with ticker symbol IOVA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Iovance Biotherapeutics
Iovance Biotherapeutics offers a comprehensive portfolio of products and services, including Amtagvi and Proleukin. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Amtagvi is developed for advanced cancer treatment therapies.
Proleukin is utilized in cancer immunotherapy treatment solutions.
Unlock access to complete
Unlock access to complete
Leadership Team
35 people
Operations Team
14 people
Software Development Team
12 people
Legal and Compliance
6 people
Human Resources and Administration
4 people
Senior Team
4 people
Product Management Team
3 people
Manufacturing Team
3 people
Unlock access to complete
Funding Insights of Iovance Biotherapeutics
- Total Funding Total Funding
- Total Rounds 11
- Last Round Post-IPO — $100.0M
-
First Round
First Round
(17 Sep 2010)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2016 | Amount | Post-IPO - Iovance Biotherapeutics | Valuation |
investors |
|
| Jun, 2016 | Amount | Post-IPO - Iovance Biotherapeutics | Valuation |
investors |
|
| Jun, 2016 | Amount | Post-IPO - Iovance Biotherapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Iovance Biotherapeutics
Iovance Biotherapeutics has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Orbimed, Frazier Healthcare Partners and Perceptive Advisors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare sector private equity investments are managed by the firm.
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Iovance Biotherapeutics
Iovance Biotherapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Proleukin. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Information on cancer drugs is provided via an online platform.
|
1998 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Iovance Biotherapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Iovance Biotherapeutics Comparisons
Competitors of Iovance Biotherapeutics
Iovance Biotherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| domain | founded_year | HQ Location |
Targeted therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Iovance Biotherapeutics
Frequently Asked Questions about Iovance Biotherapeutics
When was Iovance Biotherapeutics founded?
Iovance Biotherapeutics was founded in 2007 and raised its 1st funding round 3 years after it was founded.
Where is Iovance Biotherapeutics located?
Iovance Biotherapeutics is headquartered in San Carlos, United States. It is registered at San Carlos, California, United States.
Who is the current CEO of Iovance Biotherapeutics?
Robert T Brooke is the current CEO of Iovance Biotherapeutics. They have also founded this company.
How many employees does Iovance Biotherapeutics have?
As of Dec 31, 2024, the latest employee count at Iovance Biotherapeutics is 838.
What is the annual revenue of Iovance Biotherapeutics?
Annual revenue of Iovance Biotherapeutics is $164.07M as on Dec 31, 2024.
What does Iovance Biotherapeutics do?
Iovance Biotherapeutics is engaged in pioneering cancer treatment by leveraging the human immune system. The company is dedicated to developing Tumor Infiltrating Lymphocyte (TIL) therapies and Peripheral Blood Lymphocyte (PBL) therapies for solid tumors and blood cancers. Solutions are personalized to target diverse cancer cells unique to each patient. Research and clinical trials are conducted across multiple advanced cancer types, including melanoma, NSCLC, and endometrial cancer. Manufacturing is supported by a state-of-the-art facility in Philadelphia. The focus is placed on next-generation approaches to enhance cancer treatment outcomes.
Who are the top competitors of Iovance Biotherapeutics?
Iovance Biotherapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and argenx.
What products or services does Iovance Biotherapeutics offer?
Iovance Biotherapeutics offers Amtagvi and Proleukin.
Is Iovance Biotherapeutics publicly traded?
Yes, Iovance Biotherapeutics is publicly traded on NASDAQ under the ticker symbol IOVA.
How many acquisitions has Iovance Biotherapeutics made?
Iovance Biotherapeutics has made 1 acquisition, including Proleukin.
Who are Iovance Biotherapeutics's investors?
Iovance Biotherapeutics has 3 investors. Key investors include Orbimed, Frazier Healthcare Partners, and Perceptive Advisors.
What is Iovance Biotherapeutics's ticker symbol?
The ticker symbol of Iovance Biotherapeutics is IOVA on NASDAQ.